Blood

Article	Citations
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN	1203
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data	1176
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee	669
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia	531
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients	487
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party	366
Venous thromboembolism in cancer patients: a population-based cohort study	356
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19	246
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma	214
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia	214
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia	210
Therapeutic options in VEXAS syndrome: insights from a retrospective series	184
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs	177
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies	171
Antibody-induced procoagulant platelets in severe COVID-19 infection	161
Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C	158
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma	155
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome	153
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	153
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	148
Management of AL amyloidosis in 2020	147
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set	143
Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry	141
Novel somatic mutations in UBA1 as a cause of VEXAS syndrome	141
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy	138

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study	136
Association of clonal hematopoiesis with chronic obstructive pulmonary disease	136
Prothrombotic immune thrombocytopenia after COVID-19 vaccination	135
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial	131
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation	129
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results	128
Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2	125
Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset	124
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells	124
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study	123
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis	123
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial	122
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose	122
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype	122
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies	122
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells	121
Redefining outcomes in immune TTP: an international working group consensus report	121
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma	120
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression	119
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP	117
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma	117
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study	115
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity	114
A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma	114
Real-world experience with caplacizumab in the management of acute TTP	112
Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study	112
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort	111
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis	111
BCL2 and MCL1 inhibitors for hematologic malignancies	110
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines	110
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial	110
piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL	109
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study	109
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein	109
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an	109
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin	108
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma	106
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner	105
Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy	105
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study	105
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated withpiggyBac-modified CD19 CAR T cells	105
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results	104
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis	104
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome	104
Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke	102
Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells	100
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel	100
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals	100
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma	100
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma	99

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination	97
Platelets and extracellular vesicles and their cross talk with cancer	97
Cancer immunoediting and immune dysregulation in multiple myeloma	96
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein	96
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia	96
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy	95
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents	95
Emicizumab for the treatment of acquired hemophilia A	95
Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group	95
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know	94
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal	93
Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease	93
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML	93
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults	92
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CA	91
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myel	90
A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex–mediated DNA replication	89
Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL	89
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma	88
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity	87
Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation	87
How I treat paroxysmal nocturnal hemoglobinuria	87
Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis	86
Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production	86
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study	86
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL	86
COVID-19 in patients with hematologic malignancy	85
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma	84
Comprehensive analyses of B-cell compartments across the human body reveal novel subsets and a gut-resident memory phenotype	83
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies	83
The relationship between ABO blood group, von Willebrand factor, and primary hemostasis	83
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas	82
Primary central nervous system lymphoma	82
Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues	81
Genomic profiling for clinical decision making in lymphoid neoplasms	81
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias	81
Highly accurate differentiation of bone marrow cell morphologies using deep neural networks on a large image data set	81
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition	80
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?	80
Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment	80
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab	80
TET2-mutant clonal hematopoiesis and risk of gout	80
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial	79
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial	78
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial	78
Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant	78
Plasminogen: an enigmatic zymogen	78
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials	78
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE	78
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL	77
How I treat cold agglutinin disease	77
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL	77
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis	77
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC	75
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations	75
Germ lineDDX41mutations define a unique subtype of myeloid neoplasms	75
The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial	75
PKM2 promotes neutrophil activation and cerebral thromboinflammation: therapeutic implications for ischemic stroke	75
RNF217 regulates iron homeostasis through its E3 ubiquitin ligase activity by modulating ferroportin degradation	74
IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice	74
Vasculopathy in COVID-19	74
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA	74
Single-cell analysis of ploidy and the transcriptome reveals functional and spatial divergency in murine megakaryopoiesis	74
Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis	73
Mechanistic insights and potential therapeutic approaches forNUP98-rearranged hematologic malignancies	73
CD63 is regulated by iron via the IRE-IRP system and is important for ferritin secretion by extracellular vesicles	73
T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis	73
Lessons to learn from tumor-educated platelets	72
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group	72
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial	72
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial	71
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL	71
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR	71
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms	71
Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency	71
Mutational landscape of gray zone lymphoma	71
Molecular classification improves risk assessment in adult BCR-ABL1–negative B-ALL	70
Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients	70
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Trans	70
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity	70

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition	69
Adult blood stem cell localization reflects the abundance of reported bone marrow niche cell types and their combinations	69
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemi	69
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide	69
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma	69
Relationship between clone metrics and clinical outcome in clonal cytopenia	68
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission	68
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia	68
Allogeneic natural killer cell therapy	68
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities	67
Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project	67
Hemochromatosis classification: update and recommendations by the BIOIRON Society	67
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy	67
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors	67
Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with	67
Neutrophils in acute inflammation: current concepts and translational implications	67
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets	66
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity	66
Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma	65
The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation	65
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma	65
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma	65
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis	65
CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease	65
A comprehensive transcriptome signature of murine hematopoietic stem cell aging	65
Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE	64
Acalabrutinib in treatment-naive chronic lymphocytic leukemia	64
An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis	64
The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications	64
Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity	63
Neutrophil HIF-1α stabilization is augmented by mitochondrial ROS produced via the glycerol 3-phosphate shuttle	63
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia	62
KSHV/HHV8-mediated hematologic diseases	62
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis	62
Very long chain fatty acid metabolism is required in acute myeloid leukemia	62
Platelet MHC class I mediates CD8+ T-cell suppression during sepsis	62
Aspirin and antiplatelet treatments in cancer	61
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma	61
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients	61
Vacuolization of hematopoietic precursors: an enigma with multiple etiologies	61
How I treat warm autoimmune hemolytic anemia	61
Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study	60
Clinical insights into the origins of thrombosis in myeloproliferative neoplasms	60
Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL	60
Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease	60
Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma	60
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study	60
Fetal hemoglobin in sickle cell anemia	60
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages	60
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions	60
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia	59
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study	59
Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs	59
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia	59
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma	59
The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML	59
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1	59
Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML	59
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers	59
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither	59
Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes	58
Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity	58
Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells	58
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models	58
Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies	58
Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study	58
Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin	58
The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms	58
Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function	57
Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the R	57
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma	57
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial	57
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma	57
Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma	57
Primary vitreoretinal lymphoma: a diagnostic and management challenge	57
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia	56
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia	56
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients	56
RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Resu	56
A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination	56
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Res	56
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma	56
IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics	55
Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins	55
Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation	55
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP	55
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy	55
Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?	55
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting	55
How I treat pediatric acute myeloid leukemia	55
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP	55
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Resul	55
Hematologic cancers in individuals infected by HIV	55
Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma	54
Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma	54